Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs placebo in previously treated Asian advanced hepatocellular carcinoma
CTR20160696Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Merck & Co.. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20160696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160696.